Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis (Independent)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00710788
Recruitment Status : Completed
First Posted : July 4, 2008
Last Update Posted : February 12, 2013
Information provided by (Responsible Party):
Dr Biagio Di Iorio, Azienda Sanitaria ASL Avellino 2

July 2, 2008
July 4, 2008
February 12, 2013
January 2007
September 2010   (Final data collection date for primary outcome measure)
death due to cardiac arrhythmias or as sudden cardiac death defined as any deaths coded as "cardiac arrest, cause unknown" or "cardiac arrhythmia" without any exclusions [ Time Frame: 2 years ]
death [ Time Frame: 2 years ]
Complete list of historical versions of study NCT00710788 on Archive Site
QT interval; PWV; mortality for acute myocardial infarction, cerebral vascular accident and heart failure; Non-CV mortality [ Time Frame: 2 years ]
QT interval [ Time Frame: 2 years ]
Not Provided
Not Provided
Reduce Cardiovascular Calcifications to Reduce QT Interval in Dialysis
Interventional, Multicenter, Prospective, Randomized Trial to Slow Down the Progression of Cardiovascular Calcifications to Reduce QTd in Incident Dialysis Patients
Research proposal to evaluate the impact of different phosphate binders on the progression of cardiovascular calcification and QT dispersion in new haemodialysis patients.
The risk of developing cardiovascular diseases in patients on hemodialysis is higher than in general population. Higher levels of serum phosphate are associated with adverse cardiovascular outcomes, especially in the setting of overt hyperphosphatemia. Given the biological importance of serum phosphorus, it is conceivable that also within the normal range values the higher serum phosphate levels may be associated with the worst outcome. Several paper have shown that vascular calcifications in dialysis patients are associated with increased relative risk of death; it has also been demonstrated in uremic patients that vascular calcifications decrease arterial elasticity. We previously observed that vascular calcification directly correlate with QT interval (QTc) as well as QT dispersion (QTd) in dialysis. Also, QT correction (obtained by the correction of phosphoremia and dyslipidemia) can ameliorate the development of arrhythmia and sudden death. Aim of this study is to evaluate the relationship between vascular calcifications and both QTd increase and mortality in incident hemodialysis patients, and to investigate the efficacy of sevelamer to reduce vascular calcifications and QTd.
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Cardiovascular Mortality
  • Drug: sevelamer phosphate-binders
    1600 mg/day for 2 years
    Other Name: Renagel
  • Drug: Calcium Carbonate
    Calcium carbonate 1 g/day for 2 years
  • Experimental: 1
    sevelamer as Phosphate-binder treatment
    Intervention: Drug: sevelamer phosphate-binders
  • Active Comparator: 2
    Calcium carbonate
    Intervention: Drug: Calcium Carbonate

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
September 2011
September 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • incident patients on haemodialysis (CKD stage 5);
  • an informed consent will be provided at the study entry.

Exclusion Criteria:

  • congenital prolongation of QT segment syndrome;
  • QTc >440 ms; increased QTd;
  • bradycardia <50 bpm;
  • sintomatic arrhythmia or any other significant heart problems;
  • electrolyte unbalances (especially hypokalemia, hypomagnesemia, hypocalcemia);
  • abnormal liver function tests;
  • hypothyroidism.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Dr Biagio Di Iorio, Azienda Sanitaria ASL Avellino 2
Azienda Sanitaria ASL Avellino 2
Not Provided
Study Chair: Biagio R Di Iorio, MD, PhD ASL AV/2, Avellino, Italy
Principal Investigator: Loreto Gesualdo, professor Nephrology Division, Medical School, University of Foggia
Principal Investigator: Filippo Aucella, MD ASL FG, Italy
Principal Investigator: Walter De Simone, MD AO MOscati, Avellino, Italy
Principal Investigator: Mario Migliorati, MD Dialysis, Torre del Greco, Italy
Principal Investigator: Domenico Santoro, MD Nephrology Division, Medical School, University of Messina, Italy
Principal Investigator: Pasquale Guastaferro, MD Nephrology Division, ASL AV1, Sant'Angelo de Lomnardi, Italy
Principal Investigator: Luigi Chiuchuilo, MD Dialysis, Avellino, Italy
Principal Investigator: Vincenzo Tedesco, MD Dialysis, Montella, Italy
Azienda Sanitaria ASL Avellino 2
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP